UBS raised the firm’s price target on Cencora to $267 from $251 and keeps a Buy rating on the shares. It appears that better Covid vaccine sales drove only a small part of the upward revision to FY24 guidance, the analyst tells investors in a research note. The firm sees further potential upside beyond even the guidance raise as fundamentals continue to improve.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on COR:
- Cencora Schedules Fiscal Quarter Results Discussion Webcast
- Cencora raises FY24 adjusted EPS view to $13.25-$13.50 from $12.70-$13.00
- Cencora reports Q1 adjusted EPS $3.28, consensus $2.89
- Cencora price target raised to $247 from $221 at JPMorgan
- Cencora price target raised to $240 from $220 at Argus
